| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Metastasis inhibitors are expected as new chemotherapeutic agents with little side effects. We previously discovered DHMEQ as an NF-kappa B inhibitor. It shows various anti-inflammatory and anticancer activities in animal experiments, but it contains epoxide moiety that causes instability. In the present research, we designed and synthesized an epoxide-free DHMEQ analog called SEMBL. SEMBL inhibited NF-kappa B as DHMEQ. It also inhibited cellular migration and invasion in ovarian carcinoma cells more strongly than DHMEQ. Moreover, it was shown to be more stable than DHMEQ in aqueous solution (published in 2017). In one hand, we previously discovered a novel plant-derived flavonoid desmal. In the present research, dismal was found to inhibit NF-kappa B. It also inhibited cellular migration and invasion in ovarian carcinoma cells (published in 2016). These inhibitors will be useful for the mechanistic study of metastasis and for the development of new chemotherapeutic agents.
|
